Items Tagged ‘refractory colorectal cancer’

October 23, 2014

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer


The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According to estimates from the American Cancer Society, more than 102,000 new cases of colon cancer and about 40,000 new cases of rectal cancer were diagnosed in […]

View full entry

Tags: Colon Cancer, colorectal cancer, News, Rectal Cancer, refractory colorectal cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, TAS-102